Literature DB >> 7805034

Translocation t(12;16)(q13;p11) in myxoid liposarcoma and round cell liposarcoma: molecular and cytogenetic analysis.

J C Knight1, P J Renwick, P Dal Cin, H Van den Berghe, C D Fletcher.   

Abstract

Translocation t(12;16)(q13;p11) is regarded as a diagnostic marker for myxoid liposarcoma. Cytogenetic data on round cell liposarcomas and combined myxoid and round cell tumors is scarce, and the genetic basis of progression of myxoid tumors to high grade, round cell lesions is unknown. We have accumulated six round cell, four combined myxoid and round cell, and three myxoid liposarcomas for analysis. t(12;16)(q13;p11) was present in three round cell lesions and was detectable in all of the tumors by DNA analysis. In each tumor type, the CHOP gene in 12q13 was rearranged and fused to the TLS gene in 16p11. A variant TLS-CHOP RNA transcript was detected by polymerase chain reaction but did not correlate with clinicopathological data. No distinguishing cytogenetic or molecular markers for round cell or mixed lesions were found. The histogenic and genetic relatedness of myxoid and round cell liposarcomas is apparent from these data.

Entities:  

Mesh:

Year:  1995        PMID: 7805034

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  44 in total

1.  Induction of a secreted protein by the myxoid liposarcoma oncogene.

Authors:  M Kuroda; X Wang; J Sok; Y Yin; P Chung; J W Giannotti; K A Jacobs; L J Fitz; P Murtha-Riel; K J Turner; D Ron
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

2.  A novel type of EWS-CHOP fusion gene in two cases of myxoid liposarcoma.

Authors:  Taisuke Hosaka; Yasuaki Nakashima; Katsuyuki Kusuzaki; Hiroaki Murata; Tomitaka Nakayama; Takeharu Nakamata; Tomoki Aoyama; Takeshi Okamoto; Kohichi Nishijo; Nobuhito Araki; Tadao Tsuboyama; Takashi Nakamura; Junya Toguchida
Journal:  J Mol Diagn       Date:  2002-08       Impact factor: 5.568

3.  Lipoblastoma in a 23-year-old male: distinction from atypical lipomatous tumor using cytogenetic and fluorescence in-situ hybridization analysis.

Authors:  Raf Sciot; Ivo De Wever; Maria Debiec-Rychter
Journal:  Virchows Arch       Date:  2003-04-05       Impact factor: 4.064

4.  Chromosomal breakage-fusion-bridge events cause genetic intratumor heterogeneity.

Authors:  D Gisselsson; L Pettersson; M Höglund; M Heidenblad; L Gorunova; J Wiegant; F Mertens; P Dal Cin; F Mitelman; N Mandahl
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

5.  A Case of Dedifferentiated LiposarcomaThat Developed in the Dermis.

Authors:  Ji Yeon Byun; You Won Choi; Hae Young Choi; Ki Bum Myung
Journal:  Ann Dermatol       Date:  2008-12-31       Impact factor: 1.444

6.  Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma.

Authors:  G D Demetri; C D Fletcher; E Mueller; P Sarraf; R Naujoks; N Campbell; B M Spiegelman; S Singer
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

7.  Fine needle aspiration biopsy diagnosis of dedifferentiated liposarcoma: Cytomorphology and MDM2 amplification by FISH.

Authors:  Hatem Q Al-Maghraby; Walid E Khalbuss; Uma N M Rao; Kathleen Cieply; Sanja Dacic; Sara E Monaco
Journal:  Cytojournal       Date:  2010-04-06       Impact factor: 2.091

Review 8.  Soft tissue tumors associated with EWSR1 translocation.

Authors:  Salvatore Romeo; Angelo P Dei Tos
Journal:  Virchows Arch       Date:  2010-02       Impact factor: 4.064

9.  Plasma levels of miRNA-155 as a powerful diagnostic marker for dedifferentiated liposarcoma.

Authors:  Aleksandar Boro; David Bauer; Walter Born; Bruno Fuchs
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

10.  Prognostic significance of grading (MIB-1 system) in patients with myxoid liposarcoma.

Authors:  U Tateishi; T Hasegawa; Y Beppu; A Kawai; N Moriyama
Journal:  J Clin Pathol       Date:  2003-08       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.